Why is NWRN.SW stock down in pre‑market trade?

The pre‑market decline to **CHF 19.38** likely reflects profit‑taking after a strong rally and positioning ahead of the earnings date on **24 Mar 2026**. Volume is above average, suggesting active selling rather than a thin‑market move.

What is Meyka AI's forecast for NWRN.SW stock?

Meyka AI's forecast model projects **CHF 17.94** monthly and **CHF 21.73** yearly. Versus the current **CHF 19.38**, that means a near‑term downside of **-7.43%** and a one‑year upside of **+12.14%**. Forecasts are model projections, not guarantees.

Which valuation metrics matter for Newron Pharmaceuticals?

Key metrics include **EPS CHF 1.24**, trailing PE **15.63**, EV/Sales **7.58**, and cash per share **CHF 2.16**. The high price/book reflects low book value per share and biotech intangible value, increasing sensitivity to clinical news.

What technical levels should traders watch for NWRN.SW stock?

Watch support at the Bollinger lower band near **CHF 18.35** and resistance at the 50‑day MA **CHF 22.36**. ATR **1.26** helps set stop levels, and RSI around **50.51** suggests neutral momentum.

CH Stocks

NWRN.SW Newron Pharmaceuticals (SIX) -7.71% pre-market 20 Feb: earnings focus

ByDanny Kontos February 20, 2026

The NWRN.SW stock opened sharply lower in pre-market trade after a sell-off that pushed the price to CHF 19.38, down -7.71% from the previous close. We view today’s move as profit-taking after strong multi‑month gains and positioning ahead of Newron’s next earnings date on 24 Mar 2026. Volume is elevated at 220,335 shares versus an average of 164,857, signalling real selling pressure rather than a thin‑market blip. For Swiss investors on the SIX, this drop raises near-term risk, with earnings and R&D progress the likely catalysts.